The Australian share market is packed with fast-growing companies, which can make choosing the right ones a real challenge. With so many appealing options, narrowing the field becomes essential.
To help simplify the process, here are three ASX growth shares that analysts are currently positive on and recommending to clients. They are as follows:
Image source: Getty Images
Goodman Group (ASX: GMG)
Investors don't normally associate property companies with high growth, yet Goodman Group continues to prove why it's an exception to the rule.
Goodman owns, develops, and manages high-specification industrial properties for many of the world's most influential companies. This includes Amazon, Tesla, and FedEx. These logistics and warehouse facilities sit at the centre of long-term structural trends such as e-commerce, supply chain modernisation, and data-driven distribution.
The company has also been leaning heavily into data centre development, a sector with enormous demand thanks to artificial intelligence, hyperscale cloud providers, and high-performance computing. This could become a major growth engine for Goodman over the coming decade.
Morgan Stanley thinks Goodman could be a top ASX growth share to buy. It has an overweight rating and $41.50 price target on its shares.
Pro Medicus Ltd (ASX: PME)
Pro Medicus specialises in advanced medical imaging software through its Visage platform, which enables radiologists to review scans with exceptional speed and efficiency. This has made Pro Medicus a preferred partner for some of the leading hospital networks in the United States, where it continues to secure sizeable multi-year contracts.
What sets the company apart is its combination of growing recurring revenue, world-class margins, and an ultra–capital-light business model, which allows it to convert most of its earnings directly into free cash flow. Few ASX growth shares can match its consistency or profitability profile. And with radiologist shortages expected to continue for some time, its outlook remains very positive.
The team at Citi recently upgraded Pro Medicus to a buy rating with a $350.00 price target.
Temple & Webster Group Ltd (ASX: TPW)
Rounding out the list is Temple & Webster, which is one of Australia's standout online retail success stories.
The company has ridden the wave of digital adoption in furniture and homewares, offering shoppers a vast range of stylish and affordable products. Its online-only model gives it structural cost advantages over traditional retailers, helping it take market share even in periods of weaker discretionary spending.
In addition, Temple & Webster continues to invest in private-label product lines, logistics, and technology to strengthen customer engagement. And, importantly, online penetration in its category remains well below levels seen in comparable markets, meaning the company still has a substantial growth runway ahead of it.
Macquarie has an outperform rating and $31.30 price target on its shares.
